Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing factor (GHRF) analog that stimulates the pituitary gland to produce and release growth hormone. It is primarily used to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution often associated with antiretroviral therapy.
A GHRF analog that stimulates growth hormone release and is used to reduce excess abdominal fat in HIV patients with lipodystrophy.
Key facts at a glance
- ATC
- H01AC06
- RxNorm
- 1044584
- Generic
- Tesamorelin
- Class
- atc-h01
- Brands
- Egrifta
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Tesamorelin is indicated for the reduction of excess visceral abdominal fat (VAT) in HIV-infected patients with lipodystrophy. This condition commonly occurs as a complication of antiretroviral therapy and is characterized by disproportionate fat accumulation in the abdominal region.
Tesamorelin is a synthetic analog of growth hormone-releasing factor (GHRF/GHRH). It binds to and stimulates GRF receptors in the pituitary gland with potency similar to endogenous GHRF, triggering the release of growth hormone. This leads to increased lipolysis (fat breakdown) in visceral adipose tissue.
Tesamorelin is administered as a daily subcutaneous injection. Common side effects include injection site reactions, arthralgia, and elevated blood glucose levels. It should not be used in patients with active malignancy, pituitary tumors, or during pregnancy. Treatment response should be monitored, and therapy may be discontinued if no improvement is observed after 6 months.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy